evoke trial semaglutide AAN 2026 AD/PD 2026: Novo Nordisk's semaglutide
Description
HR, 1.12

This medication contains Semaglutide, used to manage type 2 diabetes mellitus by mimicking the GLP-1 hormone, enhancing insulin secretion, reducing glucagon release, and slowing gastric emptying

Try a Semaglutide weight loss program with Ozempic, Wegovy or Rybelsus

This systematic review examines the potential association between semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, and the development of non-arteritic anterior ischemic optic neuropathy (NAION)

Planning to pay out of pocket if your coverage ends

- High purity compound